Literature DB >> 20886209

Do predictors exist for a successful withdrawal of preoperative prostaglandin E(1) from neonates with d-transposition of the great arteries and intact ventricular septum?

Angela Oxenius1, Maja I Hug, Ali Dodge-Khatami, Anna Cavigelli-Brunner, Urs Bauersfeld, Christian Balmer.   

Abstract

Prostaglandin E(1) (PGE(1)) is given to neonates with d-transposition of the great arteries (d-TGA) to reduce cyanosis by reopening and maintaining the patency of the ductus arteriosus. To avoid side effects, this medication can be stopped for hemodynamically stable patients after balloon atrial septostomy (BAS). A consecutive series of neonates with d-TGA and an intact ventricular septum (IVS) presenting from 2000 through 2005 was analyzed retrospectively to search for side effects of PGE(1) and to identify predictors for a safe preoperative withdrawal. The medication was stopped for hemodynamically stable patients with transcutaneous oxygen saturations higher than 80% after BAS and reinitiated for patients with an oxygen saturation lower than 65%. Patients successfully weaned were compared with those who had failed weaning in terms of atrial septal defect (ASD) size, ductus arteriosus size, and the transcutaneous oxygen saturation. Prostaglandin E(1) was initiated for all 43 neonates with d-TGA. The median maintenance dose of PGE(1) was 0.00625 μg/kg/min (range, 0.00313-0.050 μg/kg/min) for a median duration of 6 days (range, 1-12 days). For 16 patients, PGE(1) was preoperatively withdrawn but then had to be reinitiated for 7 of the 16 patients. No predictors for a successful weaning of PGE(1) were found based on ASD size, ductus arteriosus size, or oxygen saturation. The adverse effects of PGE(1) were apnea in 10 patients and fever in 19 patients. Neither seizures nor necrotizing enterocolitis was documented. Prostaglandin E(1) was successfully withdrawn for a minority of hemodynamically stable patients with d-TGA. No predictors for a successful weaning could be identified. Because apnea and fever are common side effects, withdrawal of PGE(1) after BAS may improve patient safety and comfort. In this patient group, if PGE(1) withdrawal was not well tolerated, it could be safely reinitiated. There were no serious side effects of PGE(1.).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20886209     DOI: 10.1007/s00246-010-9790-x

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  12 in total

1.  [Complications of prostaglandin E1 treatment of congenital heart disease in paediatric medical intensive care].

Authors:  H Lucron; M Chipaux; G Bosser; S Le Tacon; J P Lethor; F Feillet; G Burger; P Monin; F Marçon
Journal:  Arch Mal Coeur Vaiss       Date:  2005-05

2.  Histopathology of the arterial duct (ductus arteriosus) with and without treatment with prostaglandin E1.

Authors:  A C Gittenberger-de Groot; J L Strengers
Journal:  Int J Cardiol       Date:  1988-05       Impact factor: 4.164

3.  Prostaglandin E1 in infants with congenital heart disease: Indian experience.

Authors:  A Saxena; M Sharma; S S Kothari; R Juneja; S C Reddy; R Sharma; A Bhan; P Venugopal
Journal:  Indian Pediatr       Date:  1998-11       Impact factor: 1.411

4.  Role of balloon atrial septostomy before early arterial switch repair of transposition of the great arteries.

Authors:  B G Baylen; M Grzeszczak; M E Gleason; S E Cyran; H S Weber; J Myers; J Waldhausen
Journal:  J Am Coll Cardiol       Date:  1992-04       Impact factor: 24.094

5.  Effects of prostaglandin E1 infusion in the pre-operative management of critical congenital heart disease.

Authors:  T Ohara; H Ogata; J Fujiyama; Y Murata; J Abe; K Kakuta; S Hayamizu; S Kameyama; Y Yoshida
Journal:  Tohoku J Exp Med       Date:  1985-06       Impact factor: 1.848

6.  Prostaglandin E2 administration in infants with ductus-dependent cyanotic congenital heart disease.

Authors:  B D Thanopoulos; A Andreou; C Frimas
Journal:  Eur J Pediatr       Date:  1987-05       Impact factor: 3.183

Review 7.  Evaluation of alprostadil (prostaglandin E1) in the management of congenital heart disease in infancy.

Authors:  M A Heymann; R I Clyman
Journal:  Pharmacotherapy       Date:  1982 May-Jun       Impact factor: 4.705

8.  Side effects of therapy with prostaglandin E1 in infants with critical congenital heart disease.

Authors:  A B Lewis; M D Freed; M A Heymann; S L Roehl; R C Kensey
Journal:  Circulation       Date:  1981-11       Impact factor: 29.690

9.  Study of low dosage prostaglandin--usages and complications.

Authors:  G K Singh; L V Fong; A P Salmon; B R Keeton
Journal:  Eur Heart J       Date:  1994-03       Impact factor: 29.983

10.  Prostaglandins, ductus arteriosus, pulmonary circulation: current concepts and clinical potential.

Authors:  F Coceani; P M Olley; J E Lock
Journal:  Eur J Clin Pharmacol       Date:  1980-07       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.